Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835434 | 0.92 | CYP19A1 (0.39) | POLBALDH1A1PKMCYP19A1MAPK1 | |
| SCHEMBL13318048 | 0.90 | CYP19A1 (0.46) | POLBALDH1A1PKMCYP19A1MAPK1 | |
| SCHEMBL16449769 | 0.89 | SIGMAR1 (0.38) | POLBALDH1A1PKMGAASMN1; SMN2 | |
| SCHEMBL16675656 | 0.89 | MGLL (0.39) | POLBALDH1A1PKMCYP19A1MAPK1 | |
| SCHEMBL17190592 | 0.89 | ALDH1A1 (0.39) | POLBALDH1A1PKMCYP19A1MAPK1 | |
| SCHEMBL25010905 | 0.89 | POLB (0.36) | POLBALDH1A1PKMCYP19A1MAPK1 | |
| SCHEMBL16307670 | 0.89 | LMNA (0.43) | POLBALDH1A1PKMGAASMN1; SMN2 | |
| SCHEMBL10155348 | 0.89 | POLB (0.36) | POLBALDH1A1PKMCYP19A1MAPK1 | |
| SCHEMBL16449768 | 0.88 | LMNA (0.36) | POLBALDH1A1PKMSMN1; SMN2LMNA | |
| SCHEMBL16449765 | 0.88 | SIGMAR1 (0.40) | POLBALDH1A1GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326233-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC (CA) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326233-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | VIP, KLKB1, SERPINA3 | POLB 2994/4885ALDH1A1 4303/4885PKM 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.